Dotinurad not checked

Crystalys Therapeutics

FollowEvery change as it happens, and a Monday email
Next date
Phase 2 trial completes
Trials
3 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Over-encapsulated tablets containing active drug substance administered PO.”In the company’s words, NCT07089875 on ClinicalTrials.gov
Tested for
Gout (2 trials), Tophaceous Gout
Main trialPhase 3
“The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.”In the company’s words, NCT07089875 on ClinicalTrials.gov

Other drugs for Gout

All 12 drugs for Gout

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 29 Nov 2027 A Study of Dotinurad Versus Allopurinol in Participants With Gout
Phase 3Recruiting 31 Dec 2027 A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Phase 2Recruiting Jul 2027 A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Dotinurad

Following is part of Solo: you see every change to Dotinurad the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in